PF-Atlas › Clinical Trials › NCT06589219

Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis

CMR316 · Phase 1

Registry ID

NCT06589219

Phase

Phase 1

Status

Recruiting

Drug / intervention

CMR316

Sponsor

Calibr, a division of Scripps Research

Start

2024-08-19

Enrollment

Locations

About this trial

The purpose of this study is to assess the safety, tolerability and pharmacokinetics single and multiple inhaled doses of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis (IPF).

View NCT06589219 on ClinicalTrials.gov →

Explore related

All CMR316 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT06589219 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.